logo-loader
RNS
viewAmryt Pharma PLC

Update on AP101 EASE Phase III trial

/**/ sup{font-size:80%}h1{margin-right:0cm;margin-left:0cm;font-size:24.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .bf{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.bf{}p.cp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#5A5A5A;letter-spacing:.75pt;font-weight: bold; line-height: normal; margin-bottom: 0cm}span.cn{color:black;letter-spacing:0pt}p.cq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.cl{font-family:"Calibri","sans-serif"; color:black}p.cr{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}span.cj{font-family:"Calibri","sans-serif";color:black}p.cs{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: center}p.ct{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify} span.cg{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.cu{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.n,li.n,div.n{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.ce{font-size:10.5pt;color:black}p.cv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}span.cc{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}p.cw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-bottom:6.0pt;text-align:justify}table.cx{width:448.25pt;margin-left:-7.1pt;border-collapse:collapse}tr.bx{height:15.0pt} td.bz{width:239.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}span.ca{font-size:11.0pt;font-family: "Calibri","sans-serif"}td.by{width:187.65pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}p.cy{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;line-height:115%}span.bw{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}span.bu{font-family:"Calibri","sans-serif"}p.cz{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic}tr.bq{height:16.35pt}td.bs{width:239.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:16.35pt}td.br{width:187.65pt;padding:0cm 5.4pt 0cm 5.4pt; height:16.35pt} span.bo{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}span.bn{font-family:"Calibri","sans-serif"; color:black;background:white}span.bm{font-size:9.0pt;font-family:"Calibri","sans-serif";background:white}p.da{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.db{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.dc{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.dd{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.de{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.df{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}span.dg{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} span.bg{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.bj{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black} /**/
RNS Number : 3552R
Amryt Pharma PLC
28 February 2019
 

28 February 2019

AIM: AMYT
ESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")

 

Update on AP101 EASE Phase III trial

 

IDMC recommends study can enrol children and infants aged from 21 days to 4 years

 

Amryt, a revenue generating orphan drug company focused on acquiring, developing & commercialising products that help to improve the lives of patients where there is a high unmet medical need, today announces an update on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa ("EB").

 

Following an assessment by the trial's Independent Data Monitoring Committee ("IDMC"), the Company can now enrol infants and children with EB between the ages of 21 days to 4 years of age in to the trial. The IDMC's analysis was conducted using pharmacokinetic ("PK") data received from patients already enrolled in the trial (aged four years and older). This follows the announcement of the unblinded interim efficacy analysis in January.

 

Amryt will begin the recruitment process for infants and children into EASE immediately. The EASE trial is the largest ever global Phase III study conducted in patients with EB and Amryt expects top-line data read out in H2 2019.

 

EB is a devastating, rare genetic skin disorder that can cause skin to blister and tear from the slightest friction or trauma and can, in some cases, cause blistering and erosion of the epithelial lining of internal organs. EB is chronic, potentially disfiguring and life limiting. There are approximately 500,000 people living with EB worldwide and there are currently no approved treatments.1  It is estimated that the market potential for AP101 is more than €1 billion.

 

Joe Wiley, CEO of Amryt Pharma, commented: "Extending the age eligibility criteria for this trial is positive news and a significant step forward in addressing the unmet need in this devastating condition, which is present from birth in most cases. This development represents another milestone for Amryt as we build on our vision of becoming a global leader in rare and orphan diseases."

 

 

Enquiries:

Amryt Pharma plc

+353 (1) 518 0200

Joe Wiley, CEO

Rory Nealon, CFO/COO

 


 

Shore Capital

+44 (0) 20 7408 4090

NOMAD and Joint Broker


Edward Mansfield, Mark Percy, Daniel Bush

 


Stifel

+44 (0) 20 7710 7600

Joint Broker


Jonathan Senior, Ben Maddison

 


 

Davy

+353 (1) 679 6363

ESM Adviser and Joint Broker


John Frain, Anthony Farrell

 


Consilium Strategic Communications

+44 (0) 20 3709 5700

Matthew Neal, David Daley, Nicholas Brown


 

 1https://www.debra.org.uk/what-is-eb/what-is-eb

 

About Amryt

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases.  

 

Lojuxta is an approved treatment for adult patients with the rare cholesterol disorder - Homozygous Familial Hypercholesterolaemia ("HoFH"). This disorder impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature narrowing and blocking of blood vessels, heart attacks and strokes, even at a very young age if not properly diagnosed or receiving adequate treatment.  Lojuxta is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LDL apheresis in adult patients with HoFH.

 

Amryt is the marketing authorisation holder and has an exclusive licence to sell Lojuxta (lomitapide) across the European Economic Area, Middle East and North Africa, Switzerland, Turkey, Israel, Russia, the Commonwealth of Independent States and the non-EU Balkan states.

 

Amryt's lead drug candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no treatment.  It is currently in Phase III clinical trials. The European and US market opportunity for EB is estimated to be in excess of €1 billion.

 

In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders. 

 

For more information on Amryt, please visit amrytpharma.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
UPDCKODNBBKBOBB

Quick facts: Amryt Pharma PLC

Price: 116.5

Market: AIM
Market Cap: £183.74 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

RNS

Holdings in Company

1 week, 6 days ago

Half-year Report

2 weeks, 2 days ago

Investor Events Update

2 weeks, 2 days ago

Holding(s) in Company

2 weeks, 2 days ago

Schedule One Update

3 weeks, 1 day ago